• 1
    Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001; 79: 95462.
  • 2
    IARC. IARC handbooks on cancer prevention, Vol. 10. Cervix cancer screening. Lyon: International Agency for Research on Cancer, 2005.
  • 3
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 4
    Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010; 102: 155767.
  • 5
    Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 92936.
  • 6
    Reuschenbach M, Seiz M, von Knebel DC, et al. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012; 130: 38894.
  • 7
    Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 138594.
  • 8
    Sankaranarayanan R, Wesley RS. A practical manual on visual screening for cervical neoplasia. IARC Technical Publication No. 41. Lyon: International Agency for Research on Cancer, 2003.
  • 9
    Sellors J, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners' manual. Lyon: International Agency for Research on Cancer, 2003.
  • 10
    Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 4304.
  • 11
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 21149.
  • 12
    Tavassoéli FA, Devilee P. Pathology and genetics tumours of the breast and female genital organs. WHO classification of tumors, 3rd edn., vol. 4. Lyon: International Agency for Research on Cancer, 2003.
  • 13
    Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35: 21020.
  • 14
    Gheit T, Landi S, Gemignani F, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 2006; 44: 202531.
  • 15
    Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 48791.
  • 16
    StataCorp LP. Stata base reference manual: Release 9. College Station, TX: StataCorp LP, 2005.
  • 17
    Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 36883.
  • 18
    Sankaranarayanan R, Gaffikin L, Jacob M, et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89( Suppl 2): S4S12.
  • 19
    Sankaranarayanan R, Thara S, Sharma A, et al. Accuracy of conventional cytology: results from a multicentre screening study in India. J Med Screen 2004; 11: 7784.
  • 20
    Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004; 4: 58.
  • 21
    Missaoui N, Hmissa S, Sankaranarayanan R, et al. [p16INK4A overexpression is a useful marker for uterine cervix lesions]. Ann Biol Clin (Paris) 2010; 68: 40914.
  • 22
    Ishikawa M, Fujii T, Saito M, et al. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 2006; 16: 34753.
  • 23
    Ekalaksananan T, Pientong C, Kongyingyoes B, et al. Combined p16INK4a and human papillomavirus testing improves the prediction of cervical intraepithelial neoplasia (CIN II-III) in Thai patients with low-grade cytological abnormalities. Asian Pac J Cancer Prev 2011; 12: 177783.
  • 24
    Kuhn L, Wang C, Tsai WY, et al. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010; 24: 255361.
  • 25
    Luciani S, Munoz S, Gonzales M, et al. Effectiveness of cervical cancer screening using visual inspection with acetic acid in Peru. Int J Gynaecol Obstet 2011; 115: 536.
  • 26
    Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398406.
  • 27
    Swaminathan R, Selvakumaran R, Esmy PO, et al. Cancer pattern and survival in a rural district in South India. Cancer Epidemiol 2009; 33: 32531.
  • 28
    Sauvaget C, Fayette JM, Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011; 113: 1424.